IAP10 Rec'd PCT/PTO 22 DEC 2009

| APTURECUPLIFIED AZ DEC 7001 | | | | | | | | | | |
|---|---|---|--|------------------------------------|--|--|--|--|--|--|
| | PTO-1 01-200 | | E PATENT & TRADEMARK OFFICE | ATTORNEY'S DOCKET NUMBER 126068 | | | | | | |
| | D | ANSMITTAL LETTER TO T ESIGNATED/ELECTED OF | U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/557,922 | | | | | | | |
| | <u>C</u> | ONCERNING A FILING UN | DER 35 U.S.C. 371 | | | | | | | |
| | | IONAL APPLICATION NO. 003/006422 | INTERNATIONAL FILING DATE . May 22, 2003 | PRIORITY DATE CLAIMED | | | | | | |
| TITLE OF INVENTION COMPOUNDS AND PREPARATIONS HAVING ANTIVIRAL EFFECT | | | | | | | | | | |
| APPLICANTS FOR DO/EO/US Masao MORI; Haruo SAITO; Hideo NEMOTO; Naoki YAMAMOTO; Masao HATTORI | | | | | | | | | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | | | | | | | | | |
| 1. | 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. | | | | | | | | | |
| 2. | \boxtimes | This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. | | | | | | | | |
| 3. | Ø | This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. | | | | | | | | |
| 4. | | The US has been elected (Article 31). | | | | | | | | |
| 5. | | A copy of the International Application as filed (35 U.S.C. 371(c)(2)) | | | | | | | | |
| 1 | | a. ☐ is attached hereto (required only if not communicated by the International Bureau). | | | | | | | | |
| | | b. has been communicated by the International Bureau. | | | | | | | | |
| | | c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US). | | | | | | | | |
| 6. | | An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) | | | | | | | | |
| l | | a. ☐ is attached hereto. | | | | | | | | |
| | | b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4). | | | | | | | | |
| | | c. The International Application | n was filed in English. | | | | | | | |
| 7. | | Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) | | | | | | | | |
| | | a. are attached hereto (required only if not communicated by the International Bureau). | | | | | | | | |
| | | b. have been communicated by the International Bureau. | | | | | | | | |
| | | c. have not been made; however, the time limit for making such amendments has NOT expired. | | | | | | | | |
| | | d. have not been made and will not be made. | | | | | | | | |
| 8. | | An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). | | | | | | | | |
| 9. | \boxtimes | An oath or declaration of the inventors (35 U.S.C. 371(c)(4)). | | | | | | | | |
| 10. | | An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). | | | | | | | | |
| Items 11 to 20 below concern document(s) or information included: | | | | | | | | | | |
| 11. | | An Information Disclosure Stateme | ent under 37 CFR 1.97 and 1.98. | | | | | | | |
| 12. | | An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. | | | | | | | | |
| 13. | | A preliminary amendment. | | | | | | | | |
| 14. | | An Application Data Sheet under 37 CFR 1.76. | | | | | | | | |
| 15. | | A substitute specification. | | | | | | | | |
| 16. | \boxtimes | A power of attorney and/or change of address letter. | | | | | | | | |
| 17. | | A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 - 1.825. | | | | | | | | |
| 18. | | A second copy of the published international application under 35 U.S.C. 154(d)(4). | | | | | | | | |
| 19. | | A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). | | | | | | | | |
| 20. | \boxtimes | Other items or information: Transmittal of Power of Attorney and Statement | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

| U.S. APPLICATION NO. (if known 10/557,922 | n, see 37 C.F.R. 1.5) | ATTORNEY'S DOCKET NUMBER 126068 | | | | | | | | |
|--|---|---------------------------------|--------------------------|----------|----|--|--|--|--|--|
| 21. The following fee | s are submitted: | CALCULATIONS PTO USE ONLY | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| BASIC NATIONAL FEE (3 | | \$ | | | | | | | | |
| SEARCH FEE (37 CFR 1. | | \$ | | | | | | | | |
| International preliminary exthe USPTO as IPEA or IS industrial applicability for a national stage | | | | | | | | | | |
| International search fee (3 | 7 CFR 1.445(a)(2)) p | | | | | | | | | |
| International search report the search fee is paid | provided to USPTO | | | | | | | | | |
| All situations not provided | for above | | \$ 500.00 | | | | | | | |
| EXAMINATION FEE (37 C | | \$ | | | | | | | | |
| International preliminary examination report or written opinion prepared by the USPTO as IPEA or ISA and favorable as to novelty, inventive step, and industrial applicability for all claims presented in the application entering the national stage | | | | | | | | | | |
| Surcharge of \$130.00 for for earliest claimed priority da | urnishing the oath or | declaration later than 3 | 0 months from the | \$130.00 | | | | | | |
| TOTAL PAGES OF APPLICATION OVER | ÷ 50 | = † | x 250 = | \$ | | | | | | |
| 100 (- 100) round up to next integer | | | | | | | | | | |
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | \$ | | | | | | |
| TOTAL CLAIMS | - 20 | = | x 50.00 = | \$ | | | | | | |
| INDEPENDENT CLAIMS | - 3 | = | x 200.00 = + 360.00 = | \$ | | | | | | |
| MULTIPLE DEPENDENT | CLAIM(S)(if applicabl | \$ | | | | | | | | |
| Applicant claims amall | \$130.00 | | | | | | | | | |
| Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½. | | | | | | | | | | |
| | | \$130.00 | | | | | | | | |
| Processing fee of \$130.00 the earliest claimed priority | for furnishing the Eng date (37 CFR 1.492) | glish translation later th | an 30 months from | \$ | | | | | | |
| | | \$130.00 | | | | | | | | |
| Fee for recording the enclo accompanied by an approp | Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + TOTAL FEES ENCLOSED = \$130.00 | | | | | | | | | |
| | | \$130.00 | | | | | | | | |
| /28/2005 ATRAN1 0000013 FC:1617 | 0 10557922 | Amount to be refunded: | \$ | | | | | | | |
| | 130,00 gp | £120.00 to asses the a | hava fana ia analana | charged: | \$ | | | | | |
| a. | | | | | | | | | | |
| c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0461. A duplicate copy of this sheet is enclosed. | | | | | | | | | | |
| d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. | | | | | | | | | | |
| NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. | | | | | | | | | | |
| The state of the s | SEND ALL CORRESPONDENCE TO: | | | | | | | | | |
| OLIFF & BERRIDGE, PLC Customer Number: 25944 NAME: lamés / Oliff | | | | | | | | | | |
| REGISTRATION NUMBER: 27,075 | | | | | | | | | | |
| Date <u>December 22, 20</u> | Date <u>December 22, 2005</u> NAME: Jesse O. Collier REGISTRATION NUMBER: 53,839 | | | | | | | | | |
| | | | • | | | | | | | |

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Masao MORI et al.

Application No.: 10/557,922

Filed: November 22, 2005

Docket No.: 126068

For:

COMPOUNDS AND PREPARATIONS HAVING ANTIVIRAL EFFECT

TRANSMITTAL OF POWER OF ATTORNEY AND STATEMENT UNDER 37 CFR § 3.73(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith is a Power of Attorney from the Assignee.

In compliance with 37 CFR §3.73(b), the undersigned hereby states that LEAD CHEMICAL CO., LTD. is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors of the patent application identified above. A copy of the assignment is attached hereto and is concurrently being submitted for recordation.

The undersigned is authorized to act on behalf of the assignee.

In accordance with 37 CFR §1.36(a), submission of this Power of Attorney revokes any powers of attorney previously given.

ALL CORRESPONDENCE IN CONNECTION WITH THIS APPLICATION SHOULD BE SENT TO OLIFF & BERRIDGE, PLC, CUSTOMER NO. 25944, TELEPHONE (703) 836-6400.

Respectfully submitted,

Registration No. 36,430

JSA/mps

Date: December 22, 2005